Obesity
Viking Therapeutics’ Oral Weight Loss Drug VK2735 Shows Promising Phase 1 Results
VK2735, Viking Therapeutics, oral weight loss drug, GLP-1/GIP dual agonist, obesity treatment, Phase 1 trial results
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Boehringer Ingelheim Discontinues NPY2 Obesity Drug Development with Gubra, Focuses on Triple-Agonist Candidate
Boehringer Ingelheim, Gubra, obesity drug, NPY2, triple-agonist, BI 3034701, clinical trials
FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy
FDA, Novo Nordisk, Ozempic, Wegovy, drug shortage, semaglutide, obesity treatment, type 2 diabetes treatment
Eli Lilly’s Stock Plummets Following Q3 Earnings Miss and Reduced Revenue Forecast
Eli Lilly, Q3 earnings, revenue forecast, stock drop, diabetes drugs, weight-loss drugs, obesity drug sales
Noom and Waltz Health Collaborate on Affordable GLP-1 Weight Loss Program
Noom, Waltz Health, GLP-1, weight loss, affordable, medication management, obesity treatment
Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes
GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment
Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership
Eli Lilly, UK life sciences, £279 million investment, Lilly Gateway Labs, obesity treatment, UK government partnership
Eli Lilly Rekindles Partnership with KeyBioscience to Bolster Obesity Drug Pipeline
Eli Lilly, obesity drugs, KeyBioscience, partnerships, weight loss treatments